Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May;18(5):52.
doi: 10.1007/s11920-016-0694-1.

Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal

Affiliations
Review

Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal

Ziva D Cooper. Curr Psychiatry Rep. 2016 May.

Abstract

Although several chemical structural classes of synthetic cannabinoids (SCs) were recently classified as Schedule I substances, rates of use and cases of serious toxic effects remain high. While case reports and media bring attention to severe SC toxicity, daily SC use resulting in dependence and withdrawal is a significant concern that is often overlooked when discussing the risks of these drugs. There is a rich literature on evidence-based approaches to treating substance use disorders associated with most abused drugs, yet little has been published regarding how to best treat symptoms related to SC dependence given its recency as an emerging clinically significant issue. This review provides a background of the pharmacology of SCs, recent findings of adverse effects associated with both acute intoxication and withdrawal as a consequence of daily use, and treatment approaches that have been implemented to address these issues, with an emphasis on pharmacotherapies for managing detoxification. In order to determine prevalence of use in cannabis smokers, a population at high risk for SC use, we obtained data on demographics of SC users, frequency of use, and adverse effects over a 3.5-year period (2012-2015) in the New York City metropolitan area, a region with a recent history of high SC use. While controlled studies on the physiological and behavioral effects of SCs are lacking, it is clear that risks associated with using these drugs pertain not only to the unpredictable and severe nature of acute intoxication but also to the effects of long-term, chronic use. Recent reports in the literature parallel findings from our survey, indicating that there is a subset of people who use SCs daily. Although withdrawal has not been systematically characterized and effective treatments have yet to be elucidated, some symptom relief has been reported with benzodiazepines and the atypical antipsychotic, quetiapine. Given the continued use and abuse of SCs, empirical studies characterizing (1) SCs acute effects, (2) withdrawal upon cessation of use, and (3) effective treatment strategies for SC use disorder are urgently needed.

Keywords: Adverse effects; Cannabis; Dependence; K2; Spice; Synthetic cannabinoid; Withdrawal.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Ziva D. Cooper is a non-compensated board member of KannaLife, Inc. and has received consultancy fees from PharmaCann, LLC. Dr. Cooper has received research funds from Insys Therapeutics.

References

    1. Wehrman J. Fake marijuana spurs more than 2,500 calls to U.S. poison centers this year alone. Alexandra: American Association of Poison Control Centers; 2010.
    1. United States Drug Enforcement Administration. Schedules of controlled substances: placement of five synthetic cannabinoids into Schedule I, 21 CFR Part 1308 [Docket No. DEA-345] Fed Regist. 2012;77:12508–12514.
    1. United States Drug Enforcement Administration. DEA makes three more “fake pot” drugs temporarily illegal today. Washington: United States Department of Justice; 2013.
    1. United States Drug Enforcement Administration. DEA news: huge synthetic drug takedown. Washington: United States Department of Justice; 2014.
    1. United States Drug Enforcement Administration. Schedules of controlled substances: temporary placement of the synthetic cannabinoid MAB-CHMINACA into Schedule I. Washington, D.C.: United States Department of Justice; 2015. [Retrieved on November 11, 2015]. http://www.deadiversion.usdoj.gov/fed_regs/rules/2015/fr0916_2.htm.

Publication types

MeSH terms

LinkOut - more resources